Literature DB >> 2440906

Comparative studies on use of fresh and frozen peripheral blood lymphocyte specimens for isolation of human immunodeficiency virus and effects of cell lysis on isolation efficiency.

D Gallo, J S Kimpton, P J Dailey.   

Abstract

Heparinized blood specimens (n = 44) and frozen peripheral blood lymphocyte (PBL) specimens (n = 42) were used to evaluate the effects of lysis on human immunodeficiency virus (HIV) isolation. In the two respective groups, 17 and 27 specimens were HIV antibody positive. In the first group there were 8 and in the second group there were 25 that were symptomatic and were classified as indicating an acquired immunodeficiency syndrome-related condition or a pre-acquired immunodeficiency syndrome-related condition by the Centers for Disease Control definition. One-half of the cells from each specimen were frozen and thawed three times before cocultivation with uninfected lymphocytes, and the isolation rates from whole and lysed cells were compared. HIV was isolated from 15 (88%) of 17 fresh specimens and from 24 (89%) of 27 frozen PBLs from HIV antibody-positive patients, and lysis had no overall effect on the isolation rate, which suggested that frozen PBLs were as suitable as fresh blood for HIV isolation attempts and that it was not necessary to maintain cell integrity when submitting PBL samples. Of 21 asymptomatic patients, 20 were culture positive, and of 23 symptomatic patients, 19 were culture positive. Specimens from the 42 antibody-negative individuals were culture negative.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440906      PMCID: PMC269195          DOI: 10.1128/jcm.25.7.1291-1294.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  5 in total

1.  Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals.

Authors:  J A Levy; J Shimabukuro
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

2.  Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus.

Authors:  C B Wofsy; J B Cohen; L B Hauer; N S Padian; B A Michaelis; L A Evans; J A Levy
Journal:  Lancet       Date:  1986-03-08       Impact factor: 79.321

3.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.

Authors:  A D Hoffman; B Banapour; J A Levy
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

4.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

Authors:  D D Ho; T R Rota; R T Schooley; J C Kaplan; J D Allan; J E Groopman; L Resnick; D Felsenstein; C A Andrews; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

5.  HTLV-III in cells cultured from semen of two patients with AIDS.

Authors:  D Zagury; J Bernard; J Leibowitch; B Safai; J E Groopman; M Feldman; M G Sarngadharan; R C Gallo
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

  5 in total
  14 in total

1.  Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients.

Authors:  D J Witt; C C Ginocchio; X P Wang; M K Kaufman
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Natural history of HIV-infection in hemophiliacs: clinical, immunological, and virological findings.

Authors:  T Kamradt; D Niese; K E Schneweis; H H Brackmann; B Kamps; B van Loo; U Hammerstein
Journal:  Klin Wochenschr       Date:  1989-10-17

3.  Isolation of human immunodeficiency virus from peripheral blood lymphocytes stored in various transport media and frozen at -60 degrees C.

Authors:  D Gallo; J S Kimpton; P J Johnson
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

4.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

Authors:  C F Barbas; D Hu; N Dunlop; L Sawyer; D Cababa; R M Hendry; P L Nara; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.

Authors:  B A Castro; C D Weiss; L D Wiviott; J A Levy
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

6.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages.

Authors:  L Z Pan; A Werner; J A Levy
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

8.  Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals.

Authors:  J B Jackson; S Y Kwok; J J Sninsky; J S Hopsicker; K J Sannerud; F S Rhame; K Henry; M Simpson; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

9.  Rapid and sensitive viral culture method for human immunodeficiency virus type 1.

Authors:  J B Jackson; R W Coombs; K Sannerud; F S Rhame; H H Balfour
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

10.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.